Поиск по репозиторию
Статья
IL-6: Relevance for immunopathology of SARS-CoV-2
2021
COVID-19 mortality is strongly associated with the development of severe pneumonia and acute respiratory distress syndrome with the worst outcome resulting in cytokine release syndrome and multiorgan failure. It is becoming critically important to identify at the early stage of the infection those patients who are prone to develop the most adverse effects. Elevated systemic interleukin-6 levels in patients with COVID-19 are considered as a relevant parameter in predicting most severe course of disease and the need for intensive care. This review discusses the mechanisms by which IL-6 may possibly contribute to disease exacerbation and the potential of therapeutic approaches based on anti-IL-6 biologics. © 2020 The Authors
Цитирование
Похожие публикации
Версии
- 1. Version of Record от 2021-04-27
Метаданные
Название журнала
- Cytokine and Growth Factor Reviews
Том
- 53
Страницы
- 13-24
Ключевые слова
- angiotensin converting enzyme 2; angiotensin II; azithromycin; CD147 antigen; hydroxychloroquine; interleukin 6; sarilumab; siltuximab; tocilizumab; IL6 protein, human; interleukin 6; monoclonal antibody; sarilumab; adult respiratory distress syndrome; coronavirus disease 2019; cytokine production; cytokine release syndrome; disease association; disease course; disease exacerbation; disease severity; down regulation; human; immunopathology; intensive care; lung fibrosis; mortality; multiple organ failure; pathogenesis; pneumonia; prediction; priority journal; protein expression; Severe acute respiratory syndrome coronavirus 2; Short Survey; virus transmission; virus virulence; Betacoronavirus; blood; Coronavirus infection; cytokine release syndrome; drug effect; immunology; lung disease; pandemic; pathogenicity; pathology; virology; virus pneumonia; Antibodies, Monoclonal, Humanized; Betacoronavirus; Coronavirus Infections; Cytokine Release Syndrome; Humans; Interleukin-6; Lung Diseases; Pandemics; Pneumonia, Viral
Издатель
- Elsevier Ltd
Тип документа
- Short Survey
Тип лицензии Creative Commons
- CC
Правовой статус документа
- Свободная лицензия
Источник
- scopus
